IMPROVING BREAST CANCER OUTCOMES BY OVERCOMING RESISTANCE TO CDK4/6 INHIBITORS

Grant number: 1177357 | Funding period: 2020 - 2024

Active

Abstract

CDK4/6 inhibitors are a new class of cancer therapy used for the treatment of metastatic breast cancer. Although they are effective, cancers invariably develop resistance to these drugs over time and the reasons for this are unclear. Here, I will study mechanisms of CDK4/6 inhibitor resistance in the lab and will test several therapeutic approaches which have the potential to overcome it. If my results are promising, these new treatments could be readily taken into clinical trials.

Related publications (3)

Scholarly works icon

Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation

Max Heckler, Lestat R Ali, Eleanor Clancy-Thompson, Li Qiang, Katherine S Ventre, Patrick Lenehan, Kevin Roehle, Adrienne Luoma, Kelly Boelaars, Vera Peters, Julia McCreary, Tamara Boschert, Eric S Wang, Shengbao Suo, Francesco Marangoni, Thorsten R Mempel, Henry W Long, Kai W Wucherpfennig, Michael Dougan, Nathanael S Gray

2021-10-01

CDK4/6 inhibitors are approved to treat breast cancer and are in trials for other malignancies. We examined CDK4/6 inhibition in m..

Scholarly works icon

Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer

Laura M Spring, Shealagh L Clark, Tianyu Li, Shom Goel, Nabihah Tayob, Elene Viscosi, Elizabeth Abraham, Dejan Juric, Steven J Isakoff, Erica Mayer, Beverly Moy, Jeffrey G Supko, Sara M Tolaney, Aditya Bardia

2021-08-04

Patients with HER2+ metastatic breast cancer are often treated with a multitude of therapies in the metastatic setting, and additi..

Scholarly works icon

CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity

April C Watt, Paloma Cejas, Molly J DeCristo, Otto Metzger-Filho, Enid YN Lam, Xintao Qiu, Haley BrinJones, Nikolas Kesten, Rhiannon Coulson, Alba Font-Tello, Klothilda Lim, Raga Vadhi, Veerle W Daniels, Joan Montero, Len Taing, Clifford A Meyer, Omer Gilan, Charles C Bell, Keegan D Korthauer, Claudia Giambartolomei

2021-01-01

Pharmacologic inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) were designed to induce cancer cell cycle arrest. Recent stu..

University of Melbourne Researchers